COMMUNIQUÉS West-GlobeNewswire

Myriad Genetics Adds 15 Clinically Actionable Genes to MyRisk® Hereditary Cancer Test to Support Evolving Clinical Needs
10/11/2025
100% of genes strongly recommended by national oncology guidelines are included in the MyRisk Test SALT LAKE CITY, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular [...]
PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025
10/11/2025
Translational study shows that multiple immunological biomarkers predict the clinical activity of PDS0101 combination therapy PDS01ADC reprograms natural killer (NK) cells to possess characteristics that make them more [...]
Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors
10/11/2025
Data presented at the 40 th Annual Society for Immunotherapy of Cancer (SITC) Meeting The spliceosome targeting payload, PH1, demonstrates the ability to induce both cancer cell cytotoxicity and activation of anti-tumor [...]
BioCardia Announces Henry Ford Health Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial
10/11/2025
SUNNYVALE, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced [...]
NewGen Announces Up to US$2 Million Share Repurchase Program
10/11/2025
The decision to initiate the program signals NewGen’s unwavering confidence in its future growth and deeply undervalued share price BANGKOK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (Nasdaq: NIVF) (“ [...]
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
10/11/2025
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for [...]
Arch Biopartners Arranges Non-Brokered Private Placement
10/11/2025
TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc ., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has arranged a non-brokered private placement offering of 480,769 [...]
Clearmind Medicine Successfully Completed First Cohort Treatment in its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
10/11/2025
Milestone advances MEAI-based therapy targeting a global Alcohol Use Disorder treatment market projected to surpass $20 billion by 2032 Vancouver, Canada, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. ( [...]
Senseonics Holdings, Inc. to Participate in the Stifel 2025 Healthcare Conference
10/11/2025
GERMANTOWN, Md., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose [...]
HOPE Therapeutics, Inc., an NRx Pharmaceuticals Subsidiary, Announces First-in-Florida Initiation of One Day (ONE-D) Depression Treatment in Partnership with Ampa Health
10/11/2025
ONE-D is the first reported protocol to achieve remission from treatment-resistant depression with a single day of treatment, using an FDA-cleared device. HOPE is one of the first Ampa deployments nationwide and is now [...]
Mainz Biomed to Attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS)
10/11/2025
BERKELEY, Calif. and MAINZ, Germany, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of [...]
Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia
10/11/2025
CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally “undruggable” targets by leveraging biomolecular condensates [...]
Voyager Reports Third Quarter 2025 Financial and Operating Results
10/11/2025
- Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 - - Sharpened focus on multi-modality pipeline with introduction of Voyager NeuroShuttle™ discovery program and small [...]
Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer
10/11/2025
HAMPTON, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ: CLDX) today announced the appointment of Teri Lawver as Senior Vice President, Chief Commercial Officer. Ms. Lawver is an accomplished global healthcare [...]
Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis
10/11/2025
Rezdiffra ® treatment significantly improved liver stiffness, fibrosis biomarkers, and markers of clinically significant portal hypertension risk in patients with compensated MASH cirrhosis Rezdiffra also improved [...]
Solésence, Inc. Appoints Yoana Dvorzsak as Vice President of Innovation and Product Integrity
10/11/2025
Dvorzsak to oversee product quality and drive innovation to support growth amidst evolving consumer needs; Named a Cosmetic Executive Women (CEW) Innovator Honoree ROMEOVILLE, Ill., Nov. 10, 2025 (GLOBE NEWSWIRE) -- [...]
Mersana Therapeutics to Host Third Quarter 2025 Conference Call on November 14, 2025
10/11/2025
CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers [...]
LifeMD to Participate in the BTIG Digital Health Forum
10/11/2025
NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services and pharmacy, today announced its participation in the virtual BTIG Digital Health Forum on [...]
Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301
10/11/2025
Appointment builds on recent FDA acceptance of New Drug Application for review and advances Cingulate’s transition toward commercialization pending FDA approval Company also strengthens its cash position by completing a [...]

Pages